ArticleThoracic cancer2021
MiR-423-5p aggravates lung adenocarcinoma via targeting CADM1.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 24 citations in OpenAlex.
- Dysregulation of the miR-4286 in diabetic kidney disease and its role in inflammatory response.Diabetology & metabolic syndrome · 2026Article
- Low Expression of Cell Adhesion Molecule 1 in Resected Gastroenteropancreatic Neuroendocrine Tumors: Relationship With Lymph Node and Distant Metastasis.Pathology international · 2026Article
- miR-423-5p/NDUFS7-mediated mitochondrial function modulation contributes to quercetin-induced attenuation of pulmonary fibrosis via extracellular matrix remodeling regulation.Non-coding RNA research · 2026Article
- Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases.Frontiers in molecular biosciences · 2026Review
- Unraveling the role of ChREBP in lung adenocarcinoma: Expression, regulatory networks, and potential functional impact.PloS one · 2026Article
- Association of FANCD2, TFPI, and CD33 genes with prognosis of lung adenocarcinoma: a bioinformatics study.Discover oncology · 2025Article
- Sirtuin family in lung adenocarcinoma.Discover oncology · 2025Review
- Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1.Molecular cancer research : MCR · 2025Article
- miR-27a-5p, miR-21-5p, miR-1246 and miR-4508: a candidate microRNA signature in the protection and regulation of viral infection in mild COVID-19.Molecular medicine (Cambridge, Mass.) · 2025Article
- Article
- Circulating MicroRNAs as Biomarkers for the Early Diagnosis of Lung Cancer and Its Differentiation from Tuberculosis.Diagnostics (Basel, Switzerland) · 2024Article
- Tuberculous Pleural Effusion-Derived Exosomal miR-130b-3p and miR-423-5p Promote the Proliferation of Lung Cancer Cells via Cyclin D1.International journal of molecular sciences · 2024Article
- LncRNA PGM5-AS1 inhibits non-small cell lung cancer progression by targeting miRNA-423-5p/SLIT2 axis.Cancer cell international · 2024Article
- COVID-19 Vaccination in Pregnancy: Pilot Study for Maternal and Neonatal MicroRNA Profiles.Vaccines · 2023Article
- MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.Molecular biotechnology · 2023Article
- lncRNA HCG11 Promotes Colorectal Cancer Cell Malignant Behaviors via Sponging miR-26b-5p.Journal of immunology research · 2023Article
- A Proteomic Approach Reveals That miR-423-5p Modulates Glucidic and Amino Acid Metabolism in Prostate Cancer Cells.International journal of molecular sciences · 2022Article
- Circ_FURIN knockdown assuages Testosterone-induced human ovarian granulosa-like tumor cell disorders by sponging miR-423-5p to reduce MTM1 expression in polycystic ovary syndrome.Reproductive biology and endocrinology : RB&E · 2022Article
- The circ-PITX1 promotes non-small cell lung cancer development via the miR-30e-5p/ITGA6 axis.Cell cycle (Georgetown, Tex.) · 2022Article
- Positive regulators of T cell proliferation as biomarkers for predicting prognosis and characterizing the immune landscape in lung adenocarcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAt present, microRNAs and its downstream genes have been regarded as influential indicators in various malignancies. Therefore, the aim of this study was to explore the relationship and molecular mechanism of the miR-423-5p and its downstream gene CADM1 in the LUAD.
methodsThe pcDNA-CADM1 was used to construct the CADM1 overexpressed cell model. The cell proliferation was determined by CCK-8 and EdU assays and the cell metastasis was performed by wound scratch and transwell chamber assays. The relationship between miR-423-5p and CADM1 were determined by bioinformatics, luciferase reporter and western blot assays.
resultsThe results revealed that the CADM1 was downregulated in LUAD tissues and cell lines. CADM1 overexpression markedly repressed the cell proliferation, migration and invasion. Moreover, the results of bioinformatics, luciferase reporter and WB assays showed that CADM1 was a target gene of miR-423-5p and the miR-423-5p expression was negatively associated with CADM1 in LUAD cell lines. Finally, rescue experiments revealed that downregulation of CADM1 could antagonize the functions of miR-423-5p inhibitor on cell proliferation and metastasis. These results indicated that miR-423-5p aggravated lung adenocarcinoma via downregulation of CADM1 expression.
conclusionsDownregulation of CADM1 could antagonize the functions of miR-423-5p inhibitor on cell proliferation and metastasis. miR-423-5p aggravated lung adenocarcinoma via downregulation of CADM1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.